nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifaximin—CYP3A4—type 2 diabetes mellitus	0.346	1	CbGaD
Rifaximin—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.056	0.152	CbGbCtD
Rifaximin—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0499	0.136	CbGbCtD
Rifaximin—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0457	0.124	CbGbCtD
Rifaximin—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0399	0.109	CbGbCtD
Rifaximin—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0361	0.0982	CbGbCtD
Rifaximin—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0273	0.0744	CbGbCtD
Rifaximin—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0262	0.0713	CbGbCtD
Rifaximin—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0262	0.0713	CbGbCtD
Rifaximin—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0248	0.0675	CbGbCtD
Rifaximin—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0185	0.0503	CbGbCtD
Rifaximin—CYP3A4—Losartan—type 2 diabetes mellitus	0.0169	0.046	CbGbCtD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—ABCC2—type 2 diabetes mellitus	0.00326	0.0898	CbGpPWpGaD
Rifaximin—NR1I2—Drug Induction of Bile Acid Pathway—CYP3A4—type 2 diabetes mellitus	0.00213	0.0589	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—type 2 diabetes mellitus	0.00187	0.0516	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—HNF4A—type 2 diabetes mellitus	0.00145	0.0401	CbGpPWpGaD
Rifaximin—CYP3A4—Felbamate Metabolism—CYP2E1—type 2 diabetes mellitus	0.00142	0.0391	CbGpPWpGaD
Rifaximin—CYP3A4—Lidocaine metabolism—CYP1A2—type 2 diabetes mellitus	0.0014	0.0387	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—type 2 diabetes mellitus	0.00127	0.0351	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—type 2 diabetes mellitus	0.00126	0.0347	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—type 2 diabetes mellitus	0.00123	0.0338	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—HNF4A—type 2 diabetes mellitus	0.00115	0.0317	CbGpPWpGaD
Rifaximin—Rifabutin—CYP1A2—type 2 diabetes mellitus	0.00109	0.241	CrCbGaD
Rifaximin—NR1I2—Nuclear Receptors—AR—type 2 diabetes mellitus	0.00101	0.0278	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—type 2 diabetes mellitus	0.000835	0.023	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—NR3C1—type 2 diabetes mellitus	0.000815	0.0225	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—AR—type 2 diabetes mellitus	0.000797	0.022	CbGpPWpGaD
Rifaximin—Rifampicin—ABCC2—type 2 diabetes mellitus	0.000775	0.17	CrCbGaD
Rifaximin—NR1I2—Nuclear Receptors—PPARA—type 2 diabetes mellitus	0.000764	0.0211	CbGpPWpGaD
Rifaximin—Rifabutin—CYP3A4—type 2 diabetes mellitus	0.000724	0.159	CrCbGaD
Rifaximin—NR1I2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—type 2 diabetes mellitus	0.00069	0.019	CbGpPWpGaD
Rifaximin—CYP3A4—Codeine and Morphine Metabolism—ABCC2—type 2 diabetes mellitus	0.000688	0.019	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—NR3C1—type 2 diabetes mellitus	0.000644	0.0178	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptors—PPARG—type 2 diabetes mellitus	0.000632	0.0174	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—PPARA—type 2 diabetes mellitus	0.000604	0.0167	CbGpPWpGaD
Rifaximin—Rifapentine—CYP3A4—type 2 diabetes mellitus	0.000548	0.121	CrCbGaD
Rifaximin—Rifampicin—CYP2E1—type 2 diabetes mellitus	0.000544	0.12	CrCbGaD
Rifaximin—Rifampicin—CYP1A2—type 2 diabetes mellitus	0.000517	0.114	CrCbGaD
Rifaximin—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—type 2 diabetes mellitus	0.000515	0.0142	CbGpPWpGaD
Rifaximin—NR1I2—Nuclear Receptor transcription pathway—PPARG—type 2 diabetes mellitus	0.000499	0.0138	CbGpPWpGaD
Rifaximin—CYP3A4—Irinotecan Pathway—ABCC2—type 2 diabetes mellitus	0.00044	0.0121	CbGpPWpGaD
Rifaximin—CYP3A4—Liver X Receptor Pathway—SREBF1—type 2 diabetes mellitus	0.000428	0.0118	CbGpPWpGaD
Rifaximin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—type 2 diabetes mellitus	0.000395	0.0109	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYB5R4—type 2 diabetes mellitus	0.000382	0.0105	CbGpPWpGaD
Rifaximin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—type 2 diabetes mellitus	0.000377	0.0104	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—IGF2BP2—type 2 diabetes mellitus	0.000373	0.0103	CbGpPWpGaD
Rifaximin—Rifampicin—CYP3A4—type 2 diabetes mellitus	0.000342	0.0753	CrCbGaD
Rifaximin—CYP3A4—Tryptophan metabolism—AANAT—type 2 diabetes mellitus	0.000341	0.00941	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NCOA6—type 2 diabetes mellitus	0.000291	0.00804	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA6—type 2 diabetes mellitus	0.000283	0.00781	CbGpPWpGaD
Rifaximin—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—type 2 diabetes mellitus	0.000269	0.00741	CbGpPWpGaD
Rifaximin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—type 2 diabetes mellitus	0.000266	0.00733	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—CYP1A2—type 2 diabetes mellitus	0.000242	0.00667	CbGpPWpGaD
Rifaximin—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—type 2 diabetes mellitus	0.000232	0.00639	CbGpPWpGaD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—type 2 diabetes mellitus	0.000227	0.00626	CbGpPWpGaD
Rifaximin—CYP3A4—Xenobiotics—CYP2E1—type 2 diabetes mellitus	0.000225	0.0062	CbGpPWpGaD
Rifaximin—CYP3A4—Xenobiotics—CYP1A2—type 2 diabetes mellitus	0.000222	0.00613	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—type 2 diabetes mellitus	0.000216	0.00597	CbGpPWpGaD
Rifaximin—CYP3A4—Tamoxifen metabolism—CYP2E1—type 2 diabetes mellitus	0.000216	0.00596	CbGpPWpGaD
Rifaximin—CYP3A4—Tamoxifen metabolism—CYP1A2—type 2 diabetes mellitus	0.000214	0.0059	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—HNF4A—type 2 diabetes mellitus	0.000199	0.00548	CbGpPWpGaD
Rifaximin—CYP3A4—Farnesoid X Receptor  Pathway—PPARGC1A—type 2 diabetes mellitus	0.000191	0.00528	CbGpPWpGaD
Rifaximin—CYP3A4—Estrogen metabolism—GSTM1—type 2 diabetes mellitus	0.000185	0.00511	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—CTGF—type 2 diabetes mellitus	0.00017	0.0047	CbGpPWpGaD
Rifaximin—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—type 2 diabetes mellitus	0.000149	0.00412	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—NOTCH2—type 2 diabetes mellitus	0.000148	0.00407	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—type 2 diabetes mellitus	0.000147	0.00405	CbGpPWpGaD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—type 2 diabetes mellitus	0.000145	0.00401	CbGpPWpGaD
Rifaximin—Headache—Pioglitazone—type 2 diabetes mellitus	0.000142	0.000578	CcSEcCtD
Rifaximin—Syncope—Irbesartan—type 2 diabetes mellitus	0.000142	0.000578	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000142	0.000577	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000141	0.000575	CcSEcCtD
Rifaximin—Discomfort—Metformin—type 2 diabetes mellitus	0.000141	0.000574	CcSEcCtD
Rifaximin—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000141	0.000574	CcSEcCtD
Rifaximin—Nausea—Glipizide—type 2 diabetes mellitus	0.00014	0.000573	CcSEcCtD
Rifaximin—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00014	0.000572	CcSEcCtD
Rifaximin—Hypotension—Valsartan—type 2 diabetes mellitus	0.00014	0.000572	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—NCOA6—type 2 diabetes mellitus	0.00014	0.00387	CbGpPWpGaD
Rifaximin—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00014	0.00057	CcSEcCtD
Rifaximin—Pain—Gliclazide—type 2 diabetes mellitus	0.00014	0.00057	CcSEcCtD
Rifaximin—Constipation—Gliclazide—type 2 diabetes mellitus	0.00014	0.00057	CcSEcCtD
Rifaximin—Tremor—Losartan—type 2 diabetes mellitus	0.000139	0.000568	CcSEcCtD
Rifaximin—Rash—Glimepiride—type 2 diabetes mellitus	0.000139	0.000567	CcSEcCtD
Rifaximin—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000139	0.000567	CcSEcCtD
Rifaximin—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000139	0.000566	CcSEcCtD
Rifaximin—Rash—Sitagliptin—type 2 diabetes mellitus	0.000139	0.000565	CcSEcCtD
Rifaximin—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000139	0.000565	CcSEcCtD
Rifaximin—Headache—Glimepiride—type 2 diabetes mellitus	0.000138	0.000564	CcSEcCtD
Rifaximin—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.000138	0.000563	CcSEcCtD
Rifaximin—Cough—Irbesartan—type 2 diabetes mellitus	0.000138	0.000562	CcSEcCtD
Rifaximin—Headache—Sitagliptin—type 2 diabetes mellitus	0.000138	0.000562	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—AR—type 2 diabetes mellitus	0.000138	0.0038	CbGpPWpGaD
Rifaximin—Anaemia—Losartan—type 2 diabetes mellitus	0.000138	0.000561	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000137	0.000558	CcSEcCtD
Rifaximin—Tinnitus—Ramipril—type 2 diabetes mellitus	0.000137	0.000557	CcSEcCtD
Rifaximin—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000136	0.000555	CcSEcCtD
Rifaximin—Flushing—Ramipril—type 2 diabetes mellitus	0.000136	0.000554	CcSEcCtD
Rifaximin—Angioedema—Losartan—type 2 diabetes mellitus	0.000136	0.000554	CcSEcCtD
Rifaximin—Infection—Metformin—type 2 diabetes mellitus	0.000136	0.000554	CcSEcCtD
Rifaximin—Insomnia—Valsartan—type 2 diabetes mellitus	0.000136	0.000554	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000135	0.000551	CcSEcCtD
Rifaximin—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000135	0.000549	CcSEcCtD
Rifaximin—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000135	0.000549	CcSEcCtD
Rifaximin—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000135	0.000549	CcSEcCtD
Rifaximin—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000135	0.000549	CcSEcCtD
Rifaximin—Shock—Metformin—type 2 diabetes mellitus	0.000135	0.000548	CcSEcCtD
Rifaximin—Insomnia—Orlistat—type 2 diabetes mellitus	0.000134	0.000547	CcSEcCtD
Rifaximin—Malaise—Losartan—type 2 diabetes mellitus	0.000134	0.000547	CcSEcCtD
Rifaximin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000134	0.000547	CcSEcCtD
Rifaximin—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000134	0.000547	CcSEcCtD
Rifaximin—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000134	0.000546	CcSEcCtD
Rifaximin—Vertigo—Losartan—type 2 diabetes mellitus	0.000134	0.000545	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000134	0.000545	CcSEcCtD
Rifaximin—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000134	0.000545	CcSEcCtD
Rifaximin—Syncope—Losartan—type 2 diabetes mellitus	0.000133	0.000544	CcSEcCtD
Rifaximin—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000133	0.000542	CcSEcCtD
Rifaximin—Skin disorder—Metformin—type 2 diabetes mellitus	0.000133	0.000541	CcSEcCtD
Rifaximin—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000132	0.000539	CcSEcCtD
Rifaximin—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000132	0.000538	CcSEcCtD
Rifaximin—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000132	0.000537	CcSEcCtD
Rifaximin—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000132	0.000537	CcSEcCtD
Rifaximin—Nausea—Glimepiride—type 2 diabetes mellitus	0.000131	0.000534	CcSEcCtD
Rifaximin—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000131	0.000533	CcSEcCtD
Rifaximin—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000131	0.000533	CcSEcCtD
Rifaximin—Asthenia—Glyburide—type 2 diabetes mellitus	0.000131	0.000532	CcSEcCtD
Rifaximin—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000131	0.000532	CcSEcCtD
Rifaximin—Anorexia—Metformin—type 2 diabetes mellitus	0.00013	0.000531	CcSEcCtD
Rifaximin—Cough—Losartan—type 2 diabetes mellitus	0.00013	0.000529	CcSEcCtD
Rifaximin—Urticaria—Gliclazide—type 2 diabetes mellitus	0.00013	0.000529	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.00013	0.000528	CcSEcCtD
Rifaximin—Fatigue—Valsartan—type 2 diabetes mellitus	0.000129	0.000528	CcSEcCtD
Rifaximin—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000129	0.000527	CcSEcCtD
Rifaximin—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000129	0.000527	CcSEcCtD
Rifaximin—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000129	0.000526	CcSEcCtD
Rifaximin—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000129	0.000526	CcSEcCtD
Rifaximin—Pruritus—Glyburide—type 2 diabetes mellitus	0.000129	0.000525	CcSEcCtD
Rifaximin—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000128	0.000523	CcSEcCtD
Rifaximin—Constipation—Valsartan—type 2 diabetes mellitus	0.000128	0.000523	CcSEcCtD
Rifaximin—Infection—Irbesartan—type 2 diabetes mellitus	0.000128	0.000522	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000128	0.000522	CcSEcCtD
Rifaximin—Fatigue—Orlistat—type 2 diabetes mellitus	0.000128	0.000521	CcSEcCtD
Rifaximin—Hypotension—Metformin—type 2 diabetes mellitus	0.000128	0.000521	CcSEcCtD
Rifaximin—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000128	0.00052	CcSEcCtD
Rifaximin—Shock—Irbesartan—type 2 diabetes mellitus	0.000127	0.000517	CcSEcCtD
Rifaximin—Pain—Orlistat—type 2 diabetes mellitus	0.000127	0.000517	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—CDKN2B—type 2 diabetes mellitus	0.000127	0.0035	CbGpPWpGaD
Rifaximin—Myalgia—Losartan—type 2 diabetes mellitus	0.000127	0.000516	CcSEcCtD
Rifaximin—Arthralgia—Losartan—type 2 diabetes mellitus	0.000127	0.000516	CcSEcCtD
Rifaximin—Chest pain—Losartan—type 2 diabetes mellitus	0.000127	0.000516	CcSEcCtD
Rifaximin—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000127	0.000516	CcSEcCtD
Rifaximin—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000127	0.000516	CcSEcCtD
Rifaximin—CYP3A4—Constitutive Androstane Receptor Pathway—PPARGC1A—type 2 diabetes mellitus	0.000126	0.00348	CbGpPWpGaD
Rifaximin—Rash—Bromocriptine—type 2 diabetes mellitus	0.000126	0.000512	CcSEcCtD
Rifaximin—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000125	0.000511	CcSEcCtD
Rifaximin—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000125	0.000511	CcSEcCtD
Rifaximin—Discomfort—Losartan—type 2 diabetes mellitus	0.000125	0.00051	CcSEcCtD
Rifaximin—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000125	0.000508	CcSEcCtD
Rifaximin—Headache—Bromocriptine—type 2 diabetes mellitus	0.000125	0.000508	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000125	0.000508	CcSEcCtD
Rifaximin—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000125	0.000508	CcSEcCtD
Rifaximin—Dry mouth—Losartan—type 2 diabetes mellitus	0.000124	0.000505	CcSEcCtD
Rifaximin—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000123	0.000501	CcSEcCtD
Rifaximin—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000123	0.0005	CcSEcCtD
Rifaximin—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000123	0.0005	CcSEcCtD
Rifaximin—Confusional state—Losartan—type 2 diabetes mellitus	0.000122	0.000499	CcSEcCtD
Rifaximin—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000122	0.000498	CcSEcCtD
Rifaximin—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000122	0.000497	CcSEcCtD
Rifaximin—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000121	0.000495	CcSEcCtD
Rifaximin—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000121	0.000494	CcSEcCtD
Rifaximin—Infection—Losartan—type 2 diabetes mellitus	0.000121	0.000492	CcSEcCtD
Rifaximin—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000121	0.000491	CcSEcCtD
Rifaximin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00012	0.000491	CcSEcCtD
Rifaximin—Tremor—Ramipril—type 2 diabetes mellitus	0.00012	0.000487	CcSEcCtD
Rifaximin—Shock—Losartan—type 2 diabetes mellitus	0.000119	0.000487	CcSEcCtD
Rifaximin—Urticaria—Valsartan—type 2 diabetes mellitus	0.000119	0.000486	CcSEcCtD
Rifaximin—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000119	0.000485	CcSEcCtD
Rifaximin—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000119	0.000484	CcSEcCtD
Rifaximin—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000119	0.000484	CcSEcCtD
Rifaximin—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000118	0.000482	CcSEcCtD
Rifaximin—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000118	0.000482	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000118	0.000481	CcSEcCtD
Rifaximin—Fatigue—Metformin—type 2 diabetes mellitus	0.000118	0.00048	CcSEcCtD
Rifaximin—Urticaria—Orlistat—type 2 diabetes mellitus	0.000118	0.00048	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000118	0.000479	CcSEcCtD
Rifaximin—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000117	0.000478	CcSEcCtD
Rifaximin—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000117	0.000478	CcSEcCtD
Rifaximin—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000117	0.000478	CcSEcCtD
Rifaximin—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000117	0.000478	CcSEcCtD
Rifaximin—Constipation—Metformin—type 2 diabetes mellitus	0.000117	0.000477	CcSEcCtD
Rifaximin—Angioedema—Ramipril—type 2 diabetes mellitus	0.000117	0.000475	CcSEcCtD
Rifaximin—Anorexia—Losartan—type 2 diabetes mellitus	0.000116	0.000472	CcSEcCtD
Rifaximin—Vomiting—Glyburide—type 2 diabetes mellitus	0.000116	0.000472	CcSEcCtD
Rifaximin—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000116	0.000471	CcSEcCtD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP2E1—type 2 diabetes mellitus	0.000115	0.00318	CbGpPWpGaD
Rifaximin—Malaise—Ramipril—type 2 diabetes mellitus	0.000115	0.000469	CcSEcCtD
Rifaximin—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000115	0.000469	CcSEcCtD
Rifaximin—Rash—Glyburide—type 2 diabetes mellitus	0.000115	0.000468	CcSEcCtD
Rifaximin—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000115	0.000467	CcSEcCtD
Rifaximin—Vertigo—Ramipril—type 2 diabetes mellitus	0.000115	0.000467	CcSEcCtD
Rifaximin—Syncope—Ramipril—type 2 diabetes mellitus	0.000114	0.000466	CcSEcCtD
Rifaximin—CYP3A4—Tryptophan metabolism—CYP1A2—type 2 diabetes mellitus	0.000114	0.00315	CbGpPWpGaD
Rifaximin—Headache—Glyburide—type 2 diabetes mellitus	0.000114	0.000465	CcSEcCtD
Rifaximin—Hypotension—Losartan—type 2 diabetes mellitus	0.000113	0.000462	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—type 2 diabetes mellitus	0.000113	0.00312	CbGpPWpGaD
Rifaximin—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000113	0.000459	CcSEcCtD
Rifaximin—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000112	0.000457	CcSEcCtD
Rifaximin—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000112	0.000457	CcSEcCtD
Rifaximin—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000112	0.000456	CcSEcCtD
Rifaximin—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000112	0.000456	CcSEcCtD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—type 2 diabetes mellitus	0.000112	0.00308	CbGpPWpGaD
Rifaximin—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000111	0.000454	CcSEcCtD
Rifaximin—Cough—Ramipril—type 2 diabetes mellitus	0.000111	0.000454	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—NR3C1—type 2 diabetes mellitus	0.000111	0.00307	CbGpPWpGaD
Rifaximin—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000111	0.000453	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000111	0.000451	CcSEcCtD
Rifaximin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000111	0.000451	CcSEcCtD
Rifaximin—Pain—Irbesartan—type 2 diabetes mellitus	0.00011	0.00045	CcSEcCtD
Rifaximin—Constipation—Irbesartan—type 2 diabetes mellitus	0.00011	0.00045	CcSEcCtD
Rifaximin—Insomnia—Losartan—type 2 diabetes mellitus	0.00011	0.000448	CcSEcCtD
Rifaximin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000109	0.000446	CcSEcCtD
Rifaximin—Urticaria—Metformin—type 2 diabetes mellitus	0.000109	0.000443	CcSEcCtD
Rifaximin—Chest pain—Ramipril—type 2 diabetes mellitus	0.000109	0.000443	CcSEcCtD
Rifaximin—Myalgia—Ramipril—type 2 diabetes mellitus	0.000109	0.000443	CcSEcCtD
Rifaximin—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000109	0.000443	CcSEcCtD
Rifaximin—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000108	0.000441	CcSEcCtD
Rifaximin—Nausea—Glyburide—type 2 diabetes mellitus	0.000108	0.000441	CcSEcCtD
Rifaximin—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000108	0.000441	CcSEcCtD
Rifaximin—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000108	0.00044	CcSEcCtD
Rifaximin—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000108	0.00044	CcSEcCtD
Rifaximin—Asthenia—Valsartan—type 2 diabetes mellitus	0.000108	0.000439	CcSEcCtD
Rifaximin—Discomfort—Ramipril—type 2 diabetes mellitus	0.000107	0.000437	CcSEcCtD
Rifaximin—Asthenia—Orlistat—type 2 diabetes mellitus	0.000106	0.000434	CcSEcCtD
Rifaximin—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000106	0.000433	CcSEcCtD
Rifaximin—Pruritus—Valsartan—type 2 diabetes mellitus	0.000106	0.000433	CcSEcCtD
Rifaximin—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000106	0.000433	CcSEcCtD
Rifaximin—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000106	0.00043	CcSEcCtD
Rifaximin—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000106	0.00043	CcSEcCtD
Rifaximin—Confusional state—Ramipril—type 2 diabetes mellitus	0.000105	0.000428	CcSEcCtD
Rifaximin—Pruritus—Orlistat—type 2 diabetes mellitus	0.000105	0.000428	CcSEcCtD
Rifaximin—Fatigue—Losartan—type 2 diabetes mellitus	0.000105	0.000427	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—PPARA—type 2 diabetes mellitus	0.000104	0.00288	CbGpPWpGaD
Rifaximin—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000104	0.000424	CcSEcCtD
Rifaximin—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000104	0.000424	CcSEcCtD
Rifaximin—Pain—Losartan—type 2 diabetes mellitus	0.000104	0.000423	CcSEcCtD
Rifaximin—Constipation—Losartan—type 2 diabetes mellitus	0.000104	0.000423	CcSEcCtD
Rifaximin—Rash—Gliclazide—type 2 diabetes mellitus	0.000103	0.00042	CcSEcCtD
Rifaximin—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000103	0.00042	CcSEcCtD
Rifaximin—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000103	0.000419	CcSEcCtD
Rifaximin—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000103	0.000418	CcSEcCtD
Rifaximin—Shock—Ramipril—type 2 diabetes mellitus	0.000102	0.000418	CcSEcCtD
Rifaximin—Headache—Gliclazide—type 2 diabetes mellitus	0.000102	0.000417	CcSEcCtD
Rifaximin—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000102	0.000416	CcSEcCtD
Rifaximin—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000102	0.000416	CcSEcCtD
Rifaximin—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000102	0.000416	CcSEcCtD
Rifaximin—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000102	0.000414	CcSEcCtD
Rifaximin—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000101	0.000412	CcSEcCtD
Rifaximin—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000101	0.00041	CcSEcCtD
Rifaximin—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.0001	0.000408	CcSEcCtD
Rifaximin—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	9.93e-05	0.000405	CcSEcCtD
Rifaximin—Dizziness—Valsartan—type 2 diabetes mellitus	9.93e-05	0.000405	CcSEcCtD
Rifaximin—Anorexia—Ramipril—type 2 diabetes mellitus	9.93e-05	0.000405	CcSEcCtD
Rifaximin—CYP3A4—Biological oxidations—MAT1A—type 2 diabetes mellitus	9.91e-05	0.00273	CbGpPWpGaD
Rifaximin—Dizziness—Orlistat—type 2 diabetes mellitus	9.81e-05	0.0004	CcSEcCtD
Rifaximin—Asthenia—Metformin—type 2 diabetes mellitus	9.81e-05	0.0004	CcSEcCtD
Rifaximin—Hypotension—Ramipril—type 2 diabetes mellitus	9.73e-05	0.000397	CcSEcCtD
Rifaximin—Nausea—Gliclazide—type 2 diabetes mellitus	9.71e-05	0.000396	CcSEcCtD
Rifaximin—Pruritus—Metformin—type 2 diabetes mellitus	9.67e-05	0.000394	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—type 2 diabetes mellitus	9.66e-05	0.00266	CbGpPWpGaD
Rifaximin—Urticaria—Losartan—type 2 diabetes mellitus	9.65e-05	0.000393	CcSEcCtD
Rifaximin—Abdominal pain—Losartan—type 2 diabetes mellitus	9.6e-05	0.000391	CcSEcCtD
Rifaximin—Body temperature increased—Losartan—type 2 diabetes mellitus	9.6e-05	0.000391	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—HNF4A—type 2 diabetes mellitus	9.56e-05	0.00264	CbGpPWpGaD
Rifaximin—Vomiting—Valsartan—type 2 diabetes mellitus	9.55e-05	0.000389	CcSEcCtD
Rifaximin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	9.51e-05	0.000387	CcSEcCtD
Rifaximin—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	9.49e-05	0.000387	CcSEcCtD
Rifaximin—Rash—Valsartan—type 2 diabetes mellitus	9.47e-05	0.000386	CcSEcCtD
Rifaximin—Dermatitis—Valsartan—type 2 diabetes mellitus	9.46e-05	0.000386	CcSEcCtD
Rifaximin—Vomiting—Orlistat—type 2 diabetes mellitus	9.43e-05	0.000384	CcSEcCtD
Rifaximin—Insomnia—Ramipril—type 2 diabetes mellitus	9.42e-05	0.000384	CcSEcCtD
Rifaximin—Headache—Valsartan—type 2 diabetes mellitus	9.41e-05	0.000383	CcSEcCtD
Rifaximin—Diarrhoea—Metformin—type 2 diabetes mellitus	9.36e-05	0.000381	CcSEcCtD
Rifaximin—Rash—Orlistat—type 2 diabetes mellitus	9.36e-05	0.000381	CcSEcCtD
Rifaximin—Dermatitis—Orlistat—type 2 diabetes mellitus	9.35e-05	0.000381	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—type 2 diabetes mellitus	9.33e-05	0.00257	CbGpPWpGaD
Rifaximin—Headache—Orlistat—type 2 diabetes mellitus	9.3e-05	0.000379	CcSEcCtD
Rifaximin—Dyspnoea—Ramipril—type 2 diabetes mellitus	9.28e-05	0.000378	CcSEcCtD
Rifaximin—CYP3A4—Tryptophan metabolism—CAT—type 2 diabetes mellitus	9.26e-05	0.00256	CbGpPWpGaD
Rifaximin—Asthenia—Irbesartan—type 2 diabetes mellitus	9.26e-05	0.000377	CcSEcCtD
Rifaximin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—type 2 diabetes mellitus	9.23e-05	0.00255	CbGpPWpGaD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—type 2 diabetes mellitus	9.21e-05	0.00254	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—type 2 diabetes mellitus	9.17e-05	0.00253	CbGpPWpGaD
Rifaximin—Pruritus—Irbesartan—type 2 diabetes mellitus	9.13e-05	0.000372	CcSEcCtD
Rifaximin—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—type 2 diabetes mellitus	9.11e-05	0.00251	CbGpPWpGaD
Rifaximin—Decreased appetite—Ramipril—type 2 diabetes mellitus	9.05e-05	0.000369	CcSEcCtD
Rifaximin—Dizziness—Metformin—type 2 diabetes mellitus	9.04e-05	0.000369	CcSEcCtD
Rifaximin—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	8.99e-05	0.000366	CcSEcCtD
Rifaximin—Fatigue—Ramipril—type 2 diabetes mellitus	8.98e-05	0.000366	CcSEcCtD
Rifaximin—Hypersensitivity—Losartan—type 2 diabetes mellitus	8.95e-05	0.000365	CcSEcCtD
Rifaximin—Nausea—Valsartan—type 2 diabetes mellitus	8.92e-05	0.000364	CcSEcCtD
Rifaximin—Constipation—Ramipril—type 2 diabetes mellitus	8.9e-05	0.000363	CcSEcCtD
Rifaximin—Diarrhoea—Irbesartan—type 2 diabetes mellitus	8.83e-05	0.00036	CcSEcCtD
Rifaximin—Nausea—Orlistat—type 2 diabetes mellitus	8.81e-05	0.000359	CcSEcCtD
Rifaximin—Asthenia—Losartan—type 2 diabetes mellitus	8.71e-05	0.000355	CcSEcCtD
Rifaximin—Vomiting—Metformin—type 2 diabetes mellitus	8.69e-05	0.000354	CcSEcCtD
Rifaximin—Rash—Metformin—type 2 diabetes mellitus	8.62e-05	0.000351	CcSEcCtD
Rifaximin—NR1I2—Generic Transcription Pathway—PPARG—type 2 diabetes mellitus	8.62e-05	0.00238	CbGpPWpGaD
Rifaximin—Dermatitis—Metformin—type 2 diabetes mellitus	8.61e-05	0.000351	CcSEcCtD
Rifaximin—Pruritus—Losartan—type 2 diabetes mellitus	8.59e-05	0.00035	CcSEcCtD
Rifaximin—Feeling abnormal—Ramipril—type 2 diabetes mellitus	8.58e-05	0.00035	CcSEcCtD
Rifaximin—Headache—Metformin—type 2 diabetes mellitus	8.57e-05	0.000349	CcSEcCtD
Rifaximin—Dizziness—Irbesartan—type 2 diabetes mellitus	8.53e-05	0.000348	CcSEcCtD
Rifaximin—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	8.52e-05	0.000347	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—PSMD6—type 2 diabetes mellitus	8.36e-05	0.0023	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—DNMT1—type 2 diabetes mellitus	8.36e-05	0.0023	CbGpPWpGaD
Rifaximin—Diarrhoea—Losartan—type 2 diabetes mellitus	8.31e-05	0.000339	CcSEcCtD
Rifaximin—Urticaria—Ramipril—type 2 diabetes mellitus	8.27e-05	0.000337	CcSEcCtD
Rifaximin—Abdominal pain—Ramipril—type 2 diabetes mellitus	8.23e-05	0.000335	CcSEcCtD
Rifaximin—Body temperature increased—Ramipril—type 2 diabetes mellitus	8.23e-05	0.000335	CcSEcCtD
Rifaximin—Vomiting—Irbesartan—type 2 diabetes mellitus	8.2e-05	0.000334	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—CTGF—type 2 diabetes mellitus	8.2e-05	0.00226	CbGpPWpGaD
Rifaximin—Rash—Irbesartan—type 2 diabetes mellitus	8.14e-05	0.000332	CcSEcCtD
Rifaximin—Dermatitis—Irbesartan—type 2 diabetes mellitus	8.13e-05	0.000331	CcSEcCtD
Rifaximin—Nausea—Metformin—type 2 diabetes mellitus	8.12e-05	0.000331	CcSEcCtD
Rifaximin—Headache—Irbesartan—type 2 diabetes mellitus	8.08e-05	0.000329	CcSEcCtD
Rifaximin—Dizziness—Losartan—type 2 diabetes mellitus	8.03e-05	0.000327	CcSEcCtD
Rifaximin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—type 2 diabetes mellitus	7.99e-05	0.0022	CbGpPWpGaD
Rifaximin—NR1I2—Generic Transcription Pathway—SERPINE1—type 2 diabetes mellitus	7.77e-05	0.00214	CbGpPWpGaD
Rifaximin—Vomiting—Losartan—type 2 diabetes mellitus	7.72e-05	0.000315	CcSEcCtD
Rifaximin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	7.67e-05	0.000313	CcSEcCtD
Rifaximin—Nausea—Irbesartan—type 2 diabetes mellitus	7.67e-05	0.000312	CcSEcCtD
Rifaximin—Rash—Losartan—type 2 diabetes mellitus	7.66e-05	0.000312	CcSEcCtD
Rifaximin—Dermatitis—Losartan—type 2 diabetes mellitus	7.65e-05	0.000312	CcSEcCtD
Rifaximin—Headache—Losartan—type 2 diabetes mellitus	7.61e-05	0.00031	CcSEcCtD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—type 2 diabetes mellitus	7.57e-05	0.00209	CbGpPWpGaD
Rifaximin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—type 2 diabetes mellitus	7.48e-05	0.00206	CbGpPWpGaD
Rifaximin—Asthenia—Ramipril—type 2 diabetes mellitus	7.47e-05	0.000304	CcSEcCtD
Rifaximin—Pruritus—Ramipril—type 2 diabetes mellitus	7.37e-05	0.0003	CcSEcCtD
Rifaximin—Nausea—Losartan—type 2 diabetes mellitus	7.21e-05	0.000294	CcSEcCtD
Rifaximin—Diarrhoea—Ramipril—type 2 diabetes mellitus	7.12e-05	0.00029	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—NOTCH2—type 2 diabetes mellitus	7.11e-05	0.00196	CbGpPWpGaD
Rifaximin—Dizziness—Ramipril—type 2 diabetes mellitus	6.89e-05	0.000281	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—AR—type 2 diabetes mellitus	6.63e-05	0.00183	CbGpPWpGaD
Rifaximin—Vomiting—Ramipril—type 2 diabetes mellitus	6.62e-05	0.00027	CcSEcCtD
Rifaximin—Rash—Ramipril—type 2 diabetes mellitus	6.57e-05	0.000268	CcSEcCtD
Rifaximin—Dermatitis—Ramipril—type 2 diabetes mellitus	6.56e-05	0.000267	CcSEcCtD
Rifaximin—Headache—Ramipril—type 2 diabetes mellitus	6.52e-05	0.000266	CcSEcCtD
Rifaximin—Nausea—Ramipril—type 2 diabetes mellitus	6.19e-05	0.000252	CcSEcCtD
Rifaximin—NR1I2—Gene Expression—CDKN2B—type 2 diabetes mellitus	6.11e-05	0.00168	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—SIRT1—type 2 diabetes mellitus	6.04e-05	0.00167	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—NR3C1—type 2 diabetes mellitus	5.36e-05	0.00148	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PPP2CA—type 2 diabetes mellitus	5.33e-05	0.00147	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—MTR—type 2 diabetes mellitus	5.03e-05	0.00139	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PPARA—type 2 diabetes mellitus	5.02e-05	0.00139	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP11A1—type 2 diabetes mellitus	4.87e-05	0.00134	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP11A1—type 2 diabetes mellitus	4.8e-05	0.00132	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—PPARG—type 2 diabetes mellitus	4.15e-05	0.00114	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP2E1—type 2 diabetes mellitus	4.02e-05	0.00111	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—CYP1A2—type 2 diabetes mellitus	3.97e-05	0.0011	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP2E1—type 2 diabetes mellitus	3.96e-05	0.00109	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—CYP1A2—type 2 diabetes mellitus	3.92e-05	0.00108	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—SERPINE1—type 2 diabetes mellitus	3.74e-05	0.00103	CbGpPWpGaD
Rifaximin—CYP3A4—Biological oxidations—GSTM1—type 2 diabetes mellitus	3.05e-05	0.00084	CbGpPWpGaD
Rifaximin—CYP3A4—Metapathway biotransformation—GSTM1—type 2 diabetes mellitus	3e-05	0.000829	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	2.32e-05	0.000641	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	2.03e-05	0.00056	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	2.03e-05	0.00056	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	1.92e-05	0.000531	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	1.92e-05	0.000531	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	1.84e-05	0.000506	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	1.69e-05	0.000467	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	1.69e-05	0.000467	CbGpPWpGaD
Rifaximin—NR1I2—Gene Expression—AKT1—type 2 diabetes mellitus	1.64e-05	0.000453	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.64e-05	0.000451	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	1.64e-05	0.000451	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	1.64e-05	0.000451	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	1.64e-05	0.000451	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	1.64e-05	0.000451	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.59e-05	0.000437	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.5e-05	0.000413	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.5e-05	0.000413	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.46e-05	0.000402	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.39e-05	0.000384	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.39e-05	0.000384	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.39e-05	0.000384	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	1.33e-05	0.000368	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	1.33e-05	0.000368	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	1.28e-05	0.000354	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	1.28e-05	0.000354	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	1.26e-05	0.000348	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	1.24e-05	0.000342	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	1.24e-05	0.000342	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	1.24e-05	0.000342	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	1.17e-05	0.000322	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	1.09e-05	0.000301	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	1.05e-05	0.000291	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	1.05e-05	0.000291	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	1.05e-05	0.000291	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	1.05e-05	0.000291	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	1.01e-05	0.000279	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	9.4e-06	0.000259	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	8.78e-06	0.000242	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	8.6e-06	0.000237	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	8.6e-06	0.000237	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	8.43e-06	0.000233	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	8.38e-06	0.000231	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	8.38e-06	0.000231	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	8.38e-06	0.000231	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	8.33e-06	0.00023	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	8.18e-06	0.000226	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	8.08e-06	0.000223	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	7.52e-06	0.000207	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	7.52e-06	0.000207	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	7.52e-06	0.000207	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	7.38e-06	0.000203	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	7.31e-06	0.000202	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	7.15e-06	0.000197	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	6.87e-06	0.00019	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	6.8e-06	0.000187	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	6.8e-06	0.000187	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	6.52e-06	0.00018	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	6.52e-06	0.00018	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	5.62e-06	0.000155	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.62e-06	0.000155	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	5.59e-06	0.000154	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	5.52e-06	0.000152	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	5.36e-06	0.000148	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	5.21e-06	0.000144	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	5.11e-06	0.000141	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	5.01e-06	0.000138	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	4.99e-06	0.000138	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	4.86e-06	0.000134	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	4.8e-06	0.000132	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	4.6e-06	0.000127	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	4.52e-06	0.000125	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	4.37e-06	0.000121	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	4.3e-06	0.000119	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	4.29e-06	0.000118	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	4.24e-06	0.000117	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	3.73e-06	0.000103	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	3.66e-06	0.000101	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	3.36e-06	9.26e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	3.21e-06	8.86e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	3.21e-06	8.86e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.94e-06	8.1e-05	CbGpPWpGaD
Rifaximin—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.48e-06	4.07e-05	CbGpPWpGaD
